BioAegis Therapeutics

Focus: BioAegis Therapeutics is a private biotechnology company focused on protein replacement therapies, headquartered in North Brunswick, NJ. The company operates in a specialized segment with a technology-driven approach to rare and genetic diseases.

Infectious Diseases Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PRIVATE

Open Jobs

About BioAegis Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow BioAegis Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Recombinant human plasma gelsolin

Volunteers

Phase 1

Clinical Trials (1)

NCT05789745A Study to Evaluate Plasma Gelsolin in Healthy Volunteers

Phase 1

Help build intelligence for BioAegis Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused therapeutic approach in protein replacement therapies offers deep technical specialization in a growing field
Private company stage allows potential for equity upside and meaningful individual impact on pipeline development
Located in North Brunswick, NJ—proximity to major pharma corridor with access to industry talent and partnerships

Watch Out For

Zero active job openings and minimal public visibility suggest company is in stealth mode or early-stage with limited hiring
Lack of disclosed funding, financials, and pipeline data creates uncertainty around runway, clinical progress, and growth trajectory

Generated by Claude from BioAegis Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Recombinant Human Plasma Gelsolin

Community-acquired Pneumonia

Phase 1/2

Clinical Trials (1)

NCT03466073A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP

Phase 1/2

Sodium Chloride 0.9% Inj pre-exposure

Decompression Sickness

Phase 2

Clinical Trials (1)

NCT06216366Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers

Phase 2